Skip to main content

Table 1 FDA approved drugs targeting VEGF/VEGFR pathways

From: Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

Name

Company

Type

Main target(s)

Approved for

Bevacizumab (Avastin)

Genentech/Roche

Humanized monoclonal antibody

VEGF-A

Metastatic colorectal carcinoma, non-small cell lung carcinoma, advanced glioblastoma, metastatic renal cell carcinoma

Sorafenib (Nexavar)

Bayer/Onyx

Small molecule TK inhibitor

VEGFR, PDGFR, Raf, cKit, FLT3

Advanced renal cell and hepatocellular carcinomas

Axitinib (Inlyta)

Pfizer

Small molecule TK inhibitor

VEGFR, PDGFR, cKit

Renal cell carcinoma

Pazopanib (Votrient)

GSK

Small molecule TK inhibitor

VEGFR, PDGFR, cKit

Advanced renal cell carcinoma, soft tissue sarcoma

Vandetanib (Caprelsa)

AstraZeneca

Small molecule TK inhibitor

VEGFR, EGFR, RET

Medullary thyroid cancer

Zaltrap (VEGF trap)

Regeneron/Sanofi-aventis

Fusion protein of Fc with VEGFR1 and R2 domains

VEGF, PlGF

Metastatic colorectal cancer

Ramucirumab (Cyramza)

Lilly/Imclone

Human monoclonal antibody

VEGFR2

Gastric/gastroesophageal junction adenocarcinoma, colorectal carcinoma, non-small cell lung carcinoma